Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Camrelizumab Plus SBRT vs Camrelizumab Alone in Oligometastatic Nasopharyngeal Carcinoma
ChiCTR2600126593Phase 3Recruiting
- Sponsor
- The Fifth Affiliated Hospital of Sun Yat-sen University
- Start
- Jun 2026
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised trial of camrelizumab in nasopharyngeal carcinoma (NPC) (2 arms), sponsored by The Fifth Affiliated Hospital of Sun Yat-sen University. Primary endpoints: Median progression-free survival (mPFS) and Quality of life (QoL). Started Jun 2026; status: recruiting.
02
Drugs
camrelizumab
03
Conditions
nasopharyngeal carcinoma (NPC)
Beyond the preview
Go deeper on ChiCTR2600126593.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600126593.